News

Morepen Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 26 September 2026.

Net profit of Morepen Laboratories rose 424.65% to Rs 56.40 crore in the quarter ended June 2026 as against Rs 10.75 crore during the previous quarter ended June 2025. Sales rose 34.07% to Rs 570.13 crore in the quarter ended June 2026 as against Rs 425.24 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales570.13425.24 34 OPM %14.485.68 - PBDT82.8824.54 238 PBT74.5315.52 380 NP56.4010.75 425 Powered by Capital Market - Live News

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 4 August 2026.

Morepen Laboratories today issued an update on its recently announced Rs 825 crore CDMO mandate. The first commercial dispatch, valued at approximately Rs 50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation and qualification stage to commercial execution stage. Having dispatched the first batch under the CDMO mandate, Morepen expects to scale the program further in the coming quarter, with additional supplies of approximately Rs 225 crore expected during Q2FY2026-27, subject to customer schedules and regulatory/commercial requirements.The Company continues to strengthen its manufacturing infrastructure to support larger CDMO opportunities. Total reactor capacity is expected to reach approximately 600 KL by the end of Q2, followed by further expansion toward 800 KL and 1,000 KL in subsequent phases.

Morepen Laboratories announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 0.2 per equity Share (i.e. 10%) , subject to the approval of the shareholders.